Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06565598 | Single-layer Robot-assisted Transperitoneal Retroperitoneal Tubeless Radical Nephrectomy | unknown | N/A | 150 | The First People's Hospital of XiushuiOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT01890590 | A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma | unknown | N/A | 46 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06548867 | Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib(CABOGEN) | unknown | — | 80 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT04503148 | Anesthesia and Cancer Study: Renal Cell Carcinoma | unknown | N/A | 562 | Seoul National University HospitalOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT06501079 | Dexamethasone Versus Mg Added to Bupivacaine Used in ESPB for Perioperative Pain Control in Patients Undergoing Unilateral Nephrectomy | unknown | N/A | 78 | National Cancer Institute, EgyptOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06428708 | [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma | unknown | Early Phase 1 | 30 | Western UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06427993 | Urine DNA Methylation Detection for Hematuria Evaluation | unknown | — | 71 | Changhai HospitalOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06424080 | Oncological and Perioperative Outcomes of Laparoscopic Versus Robotic Partial Nephrectomy for Treatment of Renal Tumors. | unknown | N/A | 20 | Menoufia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05024318 | NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma(NAPSTER) | unknown | Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT06391879 | Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma | unknown | — | 300 | Peking University First HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT04387500 | Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma | unknown | Phase 2 | 41 | West China HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06342323 | The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy(ONFM-SBRT) | unknown | — | 57 | Peking University Third HospitalOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05115812 | Renal Autotransplantation; Case Series | unknown | — | 30 | Methodist Health SystemOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06322745 | Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy | unknown | N/A | 30 | Al-Azhar UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06317298 | Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy | unknown | N/A | 36 | Peking University First HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT06148220 | A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors | unknown | N/A | 20 | Huashan HospitalOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06222125 | A Study of HB0025 Injection in Patients With Advanced Renal Cancer | unknown | Phase 2 | 100 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06182644 | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors(FAPI) | unknown | N/A | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06182735 | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma | unknown | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03108703 | Assessment of QoL and Outcomes With SBRT for RCC(AQuOS-RCC) | unknown | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04040530 | Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours | unknown | — | 187 | Region of Southern DenmarkOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06134700 | Low Pressure Versus Standard Pressure Pneumoperitoneum in Laparoscopic Nephrectomy | unknown | N/A | 44 | Institute of medicine, Maharagjung medical campusOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06129955 | Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06049030 | A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma | unknown | Phase 1 | 190 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT05534854 | Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05420519 | Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer | unknown | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05420545 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05468190 | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | unknown | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT03961698 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma(MARIO-3) | unknown | Phase 2 | 91 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05961111 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05879471 | 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 39 | Peking Union Medical College HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05739812 | The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery | unknown | N/A | 100 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05879497 | 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion | unknown | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05879510 | 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | unknown | Phase 2 | 63 | Peking Union Medical College HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05902377 | 68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma | unknown | Phase 2 | 46 | Peking Union Medical College HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT05843305 | A Study of BPI-452080 in Subjects With Solid Tumors | unknown | Phase 1 | 87 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT05285579 | Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer(ANGIOCOR) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05816642 | Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma | unknown | N/A | 500 | RenJi HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05798455 | Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Tabriz University of Medical SciencesOTHER | 1 | Apr 4, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Oct 2, 2024source: clinicaltrials